Neuland Laboratories Ltd (NEULANDLAB) — shareholding pattern, promoter holding, financials and share price
About Neuland Laboratories Ltd (NEULANDLAB)
Neuland Laboratories Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as NEULANDLAB and on the BSE under scrip code 524558. Its ISIN is INE794A01010.
Neuland Laboratories is engaged in manufacturing and selling of bulk drugs and caters to both domestic and international markets. [1]
Neuland Laboratories is an Indian API manufacturer and CDMO that develops and commercializes small-molecule APIs, intermediates and peptide APIs, operating three cGMP manufacturing facilities (USFDA/EMA/PMDA audited), a 428-strong scientific R&D team and global commercial presence across 80+ countries with total reactor volume of 1,218,000 liters and ~2,131 employees.
Q3FY26 results show total income of Rs.447.8 crore (+11.4% YoY) with EBITDA of Rs.85 crore at 19% margin (down 350bps YoY) and PAT of Rs.40.4 crore (-60% YoY); 9MFY26 capex was Rs.254 crore while net debt improved to a net cash position of Rs.(202.6) crore, reflecting heavy investment alongside deleveraging.
Listed peers in Pharmaceuticals: Acutaas Chemicals Ltd, Sai Life Sciences Ltd, Rubicon Research Ltd, Piramal Pharma Ltd, Granules India Ltd, Pfizer Ltd.
Valuation & Returns
10 Jul 2026At ₹19,551.75 a share on 10 Jul 2026, Neuland Laboratories Ltd (NEULANDLAB) was valued at a price-to-earnings ratio of 68.92x against an industry P/E of 36.41x and a price-to-book of 13.38x on a book value of ₹1,461.02 per share as of Mar 2026. Solomo computes return on equity of 19.42% and return on capital employed of 23.57% from filed results. Earnings ratios use consolidated results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 68.92x
- Industry P/E
- 36.41x
- P/B
- 13.38x
- EPS (TTM)
- ₹283.7
- Book value / share
- ₹1,461.02
- ROE
- 19.42%
- ROCE
- 23.57%
- ROA
- 12.42%
- Debt / equity
- 0.16x
- Dividend yield
- 0.06%
- EBITDA margin
- 29.89%
- 52-week range
- ₹11,500 – ₹20,072
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Neuland Laboratories Ltd (NEULANDLAB) reported revenue of ₹2,023 crore, net profit of ₹364 crore and earnings per share of ₹283.71. That compares with revenue of ₹1,477 crore and net profit of ₹260 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹776 crore and net profit ₹213 crore (consolidated).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 951 | 1,191 | 1,559 | 1,477 | 2,023 |
| Net profit (₹ cr) | 64 | 164 | 300 | 260 | 364 |
| EPS (₹) | 49.74 | 127.45 | 233.89 | 202.74 | 283.71 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | 14.72% | 16.64% | 19.31% | 36.98% |
| Profit growth | 25.58% | 35.18% | 30.57% | 39.94% |
| Stock price CAGR | 34% | 54% | 85% | 30% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 32.62% of Neuland Laboratories Ltd (NEULANDLAB) (down 0.01 pp QoQ), foreign institutional investors (FII) hold 21.08% and domestic institutional investors (DII) hold 16.51%. Promoters have pledged 2.3% of their holding. Market capitalisation was ₹25,085 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2001.
Largest disclosed public shareholders in Jun 2026: MALABAR INDIA FUND LIMITED 5.42%, MUKUL MAHAVIR AGRAWAL 3.12%, ICICI PRUDENTIAL BALANCED ADVANTAGE FUND 2.19%, MAHINDRA MANULIFE ELSS TAX SAVER FUND 1.93%, SIDDHARTH IYER 1.67%, HSBC MUTUAL FUND - HSBC SMALL CAP FUND 1.55%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 32.62% | 2.3% | 21.08% | 16.51% | 67.38% |
| Mar 2026 | 32.63% | 2.3% | 20.46% | 15.84% | 67.37% |
| Dec 2025 | 32.63% | - | 20.9% | 14.71% | 67.37% |
| Sep 2025 | 32.64% | - | 20.6% | 13.54% | 67.36% |
| Jun 2025 | 32.68% | - | 21.69% | 11.57% | 67.32% |
| Mar 2025 | 32.68% | - | 22.11% | 10.97% | 67.32% |
| Dec 2024 | 32.68% | - | 23.86% | 9.08% | 67.32% |
| Sep 2024 | 32.64% | - | 26.46% | 6.38% | 67.36% |